Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Xiao M, Xie L, Cao G, et al. CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. J Immunother Cancer 2022;10:e004022. doi: 10.1136/jitc-2021-004022
The funding statement has been updated to:
This study was supported by grants from the National Key Research and Development Program of China (NO. 2021YFC-2300602 to LY) and the National Natural Science Foundation of China (No. 32030041 to LY, No. 81702443 to SL).